Janssen pays $35m upfront to develop RNA drugs with Isis
This article was originally published in Scrip
Executive Summary
Janssen Biotech (J&J) is to pay $35m upfront and up to $800m in milestone payments to Isis Pharmaceuticals to collaborate on the development of three antisense programs to treat autoimmune disorders in the gastrointestinal tract.